Loteris Eye Drop contains Loteprednol etabonate 1% w/v, a corticosteroid indicated for the treatment of ocular inflammation and pain associated with various ophthalmic conditions. Loteprednol etabonate is a glucocorticoid receptor agonist that exerts potent anti-inflammatory effects by inhibiting the release of inflammatory mediators and suppressing leukocyte infiltration. Loteris Eye Drop is primarily prescribed for postoperative inflammation following ocular surgery, allergic conjunctivitis, and anterior uveitis. Its formulation allows for effective penetration into ocular tissues while minimizing systemic absorption, thereby reducing the risk of systemic corticosteroid-related adverse effects. The medication is administered topically, typically one to two drops in the affected eye(s) two to four times daily, with dosage adjustments based on clinical response. Common adverse effects may include mild ocular irritation, burning, or stinging upon instillation. Prolonged use may increase the risk of elevated intraocular pressure and cataract formation; therefore, patients should be monitored regularly by an ophthalmologist. Loteris Eye Drop is contraindicated in viral, fungal, or mycobacterial ocular infections. Caution is advised in patients with glaucoma or a history of corticosteroid response. This product should be used under strict medical supervision to ensure safe and effective management of ocular inflammatory conditions.